Greta Gaines Former Member of the National Board of the National Organization to Reform Marijuana Law (NORML) Joins Cannabis Science (CBIS) Team to Enhance Company's Business Development Activities

COLORADO SPRINGS, Colo., Jan. 28, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis-based pharmaceutical development and related consulting operations, appoints the well known entertainer, Greta Gaines, to coordinate promotional activities and events. Greta Gaines was voted one of the 'TOP 100 Most Influential People in Cannabis' and is a former member of the National Board of the National Organization to Reform Marijuana Law (NORML).

Greta Gaines has a sound knowledge of the cannabis industry and her international network provide a unique and valuable resource to the Company's promotion activities, including special events planned during the annual shareholder meetings in 2014 and 2015.

Robert Kane, Director and CFO of Cannabis Science, will be working closely with Greta Gaines on existing and new business promotion opportunities for the Company.

Mr. Kane said, "Greta Gaines and I have worked together for many years.  Greta's years' long passion to help patients and her active involvement in developing novel cannabis-based products are inspiring to all in our rapidly changing landscape of within the cannabis industry.  The entire Cannabis Science family is proud to welcome Greta to its growing team."

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.